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Fetal hemoglobin (HbF) improves the clinical severity of sickle cell disease (SCD), therefore, research to identify HbF-inducing
agents for treatment purposes is desirable. The focus of our study is to investigate the ability of FK228 analogues to induce HbF
using a novel KU812 dual-luciferase reporter system. Molecular modeling studies showed that the structure of twenty FK228
analogues with isosteric substitutions did not disturb the global structure of the molecule. Using the dual-luciferase system, a
subgroup of FK228 analogues was shown to be inducers of HbF at nanomolar concentrations. To determine the physiological
relevanceofthesecompounds,studiesinprimaryerythroidprogenitorsconﬁrmedthatJMA26andJMA33activatedHbFsynthesis
at levels comparable to FK228 with low cellular toxicity. These data support our lead compounds as potential therapeutic agents
for further development in the treatment of SCD.
1.Introduction
Severalclassesofpharmacologicalcompoundsthatreactivate
γ-globin gene transcription have been identiﬁed. They in-
clude cytotoxic agents, DNA methyl transferase, and his-
tone deacetylase (HDAC) inhibitors. Cytotoxic compounds
terminate actively cycling progenitors and perturb cellular
growth to trigger rapid erythroid regeneration and γ-globin
gene activation. S-stage cytotoxic drugs, such as cytosine
arabinoside [1], myleran [2], vinblastine [3], and hydrox-
yurea[4,5],induceHbFproductioninprimatesandhumans
[4, 6, 7]. The Multicenter Study of Hydroxyurea established
this agent as the ﬁrst FDA-approved treatment for SCD [7].
Hydroxyureawasshowntoreducevaso-occlusiveepisodes in
the majority of sickle-cell patients treated. However, limita-
tions to using hydroxyurea such as bone marrow suppression
[8], concerns over long-term carcinogenic complications,
and a 30% non-response rate [7, 9], make the development
of alternative therapies desirable.
The HDAC inhibitors have also been shown to be
potent HbF inducers. These agents target HDACs, which
play a dynamic role in regulating cell cycle progression and
chromatin conformation by changes in histone acetylation
status.AberranttranscriptionalrepressionmediatedbyClass
IandIIHDACshasbeendemonstratedinmanycancers[10].
Thus, HDAC inhibitors have been developed as promising
anticancer therapeutics [11]. Structurally diverse classes of
natural and synthetic HDAC inhibitors bind target HDACs
to block histone deacetylation [12]a n dp r o d u c ea no p e n
chromatin conﬁrmation and gene activation [13].
There has been great interest in HDAC inhibitors as
HbF inducers to treat SCD. They include (1) short-chain2 Anemia
fatty acids such as sodium butyrate (NaB), the ﬁrst HDAC
inhibitor reported [14, 15]; (2) the benzamides (i.e., MS-
275); (3) non cyclic and cyclic hydroxamates, like SAHA
(suberoylanilide hydroxamic acid) and TSA (Trichostatin
A); (4) cyclic peptides including FK228 (depsipeptide).
NaB induces diﬀerentiation in mouse erythroleukemia cells
via Stat5 phosphorylation and HbF synthesis through p38
mitogen-activated protein kinase signaling [16–18]. Other
fatty acids including phenylacetate and propionate [19–
21], induce HbF in erythroid progenitors, however, these
agents are rapidly metabolized and oral preparations are
not available. These published studies serve as the basis for
research eﬀorts to develop HDAC inhibitors as therapeutic
agents for SCD.
Of the hydroxamic acid derivatives, the prototype TSA
is a potent HDAC inhibitor [22, 23]. It interacts with a
divalent zinc-binding motif in the binding pocket of Class
Ia n dI IH D A C s[ 24]. Other HDAC inhibitors in the hydrox-
amic acid class include the second-generation analogues of
TSA, identiﬁed from a library screen of 600 synthesized
compounds [25]. The most widely studied TSA analogues
are SAHA and Scriptaid. SAHA targets HDAC1, 3, and 4
and inhibits prostate cancer cell growth in vitro and in
vivo [26, 27]. Recently, it was demonstrated by Pace and
colleagues that SAHA and Scriptaid induce HbF synthesis
comparable to NaB and TSA in erythroid cells and β-YAC
transgenic mice respectively [28]. However, limitations to
the further development of these agents included toxicity in
primary cells.
Another potent HDAC inhibitor is FK228, also known
as depsipeptide, isolated from Chromobacterium violaceum
[29]. This compound has a unique bicyclic structure and is
a stable pro-drug activated by the reduction of the disulﬁde
bond by glutathione to produce an active form (redFK) after
uptakeintocells[30].Thereducedsulfhydrylgroupinteracts
strongly with the zinc ion at the active site of the enzyme and
has been shown to inhibit tumor proliferation in vitro and
in vivo at nanomolar concentrations [27, 31, 32]. Recently,
FK228 was tested in the μLCRβprRluc
AγprFluc GM979 stable
cell line and erythroid progenitors grown in methylcellulose
colonies produced from peripheral blood mononuclear cells
[33]. FK228 was shown to induce HbF in both systems.
The level of γ-globin and β-globin promoter activity was
quantiﬁedindirectlyusingﬁreﬂy(γ)andrenilla(β)luciferase
activity.
Drug-mediated HbF induction remains the best ap-
proach to ameliorate the symptoms and complications of
S C D .A m o n gm a n yc o m p o u n d s ,F K 2 2 8s h o w e de ﬃcacy in
inducing γ-globin transcription at low concentrations, how-
ever, cell toxicity was observed and the drug is diﬃcult to
synthesize. It is a bicyclic depsipeptide almost exclusively
comprised of unnatural amino acids, D-valine, D-cysteine
and, (Z)-dehydrobutyrine (Dhb) as well as a (3S, 4E)-
3-hydroxy-7-mercapto-4-heptenoic acid, which is a key
componenttoformthehighlyconstrainedbicyclicstructure.
The high content of the unnatural amino acids and the
constrained bicyclic structure make it extremely stable in
physiological condition. Simon and coworkers ﬁrst reported
its total synthesis in 1996 [34], and suggested a laborious
synthetic route with moderate yield (18% overall yield with
over 16 steps).
Despite its exceptionally high in vitro and in vivo
activity, FK228 has not been explored due to its non-trivial
and challenging synthesis, which hampered its production
and the design of analogues. The latter would aide our
understanding of the molecular mechanism of FK228 and to
achieve higher potency and selectivity for HbF induction. In
fact, only a few FK228 analogues have been created to date
even after intensive synthetic eﬀorts were made [34–36]. To
circumvent this problem, we used in silico structure analysis
and molecular modeling to design twenty FK228 structural
analogues that can be easily synthesized [37]. Furthermore,
two isosteric substitutions were made without altering its
global conformation.
The objective of our study was to investigate the ability
of the newly synthesized FK228 analogues to induce γ-
globin gene transcription using a dual luciferase-based assay
system. We identiﬁed two lead compounds, JMA26 and
JMA33, which induce HbF expression in primary erythroid
progenitors. The potential of HDAC enzymes as druggable
targets in the treatment of SCD is discussed.
2.MaterialsandMethods
2.1. Synthesis of FK228 Analogues. The synthesis of all FK228
analogues described in this study was accomplished by
following the previously reported solid-phase synthetic pro-
cedure outlined in Scheme 1 [37]. Brieﬂy, S-trityl cysteamine
was loaded on aminomethylated polystyrene (AM-PS) resin
that was previously functionalized with a backbone amide
linker (BAL) [38]. The resulting secondary amine 1 was then
coupled with the ﬁrst amino acid, Fmoc-L-Asp(OAl) to give
the aspartylcysteamine 2 with high yield (98%). Thus, the
aspartylcysteamine moiety designed to replace the heptenoic
acid in the native FK228, was constructed in a single reaction
step. The remaining four amino acids were introduced
sequentially using the standard N-Fmoc/tBu solid-phase
peptide synthesis strategy to build the linear pentapeptides
6a-f. After the allyl and N-Fmoc protecting groups were
removed, the macrolactams 7a-f were formed with HBTU
(O-benzotriazole-N,N,N ,N -tetramethyluronium hexaﬂuo-
rophosphate) as a coupling reagent with high yields and
purity (>95%). S-Trityl protecting groups were removed
with dilute 1% triﬂuoroacetic acid and the resulting free
thiols were oxidized with iodine to produce the bicyclic
FK228 analogues. The analogues were cleaved from the resin
with TFA (>95%) and characterized by reverse phase—
high performance liquid chromatography and electrospray
ionization mass spectrometry.
2.2. Cell Culture. Human KU812 leukemia cells were grown
in Iscove’s Modiﬁed Dulbecco’s medium (IMDM) (Invitro-
gen, Carlsbad, CA) with 10% fetal bovine serum (Atlanta
Biologicals, Atlanta, GA), penicillin (100 U/mL), and strep-
tomycin (0.1mg/mL). The cells were incubated at 37◦Cw i t h
5% CO2. Cell count and viability were determined using a
hemocytometer and 2% Trypan blue exclusion. InductionsAnemia 3
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Scheme 1: Synthesis of FK228 analogues. Shown in the schematic are the steps, reagents, and conditions used for FK228 analogue synthesis.
Compounds1–7aretheintermediatesduringthesynthesis.Forsteps7a–f,thediﬀerentR1 andR2 groupsubstitutionsweremadetogenerate
thevariousJMAanalogues shown.Symbols:(a)NaBH3CN;(b)Fmoc-Asp(OAl),DIC;(c)Piperidine;(d)Fmoc-AA1,HBTU;(e)Fmoc-AA2,
HBTU; (f) Fmoc-D-Cys(Trt), HBTU; (g) Fmoc-D-Val, HBTU; (h) Pd(PPh3)4, DMBA; (i) HBTU; (j) 1% TFA; (k) I2;( l )T F A( >95%).
were performed with one million cells treated for 48hr with
the following drugs purchased from Sigma (St Louis, MO):
50μM Hem (hemin), 2mM NaB (sodium buytrate), 0.5μM
TSA, 10mM Cys (cysteine), 1.5nM FK228, and 100μMH U
(hydroxyurea). We also tested 5μM SAHA, a gift from Merck
& Co. Inc. (Whitehouse Station, NJ).
2.3. KU812 Stable Lines. K U 8 1 2s t a b l ec e l ll i n e sw e r ec r e a t e d
by co-transfecting wild-type KU812 cells with pEGFP-NI
(G418 selectable marker) and the μLCRβprRluc
AγprFluc dual-
reporter a kind gifts from Dr. George Stamatoyannopoulos
(University of Washington). Brieﬂy, the 315-bp human β-
globin gene promoter sequence was inserted upstream of
the Renilla along with a polyadenylation signal downstream
to create PβprRluc. Likewise, 1.4 kb of human Aγ-globin
promoter was inserted upstream of ﬁreﬂy luciferase to
create AγprFluc.T h eμLCR (locus control region), PβprRluc,
and AγprFluc fragments were subsequently cloned into the
mammalian vector, pRL-null [39].
The dual-luciferase reporter lines were produced using
10μg each of linearized μLCRβprRluc
AγprFluc and pEGFP-NI
plasmids co-transfected into KU812 cells by electroporation4 Anemia
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Figure 1: Structures of FK228 analogues. (a) The parent compound FK228 was transformed into novel structural analogues by two isosteric
substitutions. The modiﬁcation of the trans-double bond and ester linkage in the native FK228 with two isosteric amide functional groups
allows facile synthesis of analogues as well as retention of the same backbone structure. Various amino acids such as Val, Ala, Phe, 2-Nal, and
Lys were introduced to investigate potency of the analogues. (b) Superimposed structures of FK228 (green) and a modiﬁed FK228 analogue
(orange).
at 260V, 975μF (Bio-Rad, Hercules CA). After 72hr, G418
was added at a concentration of 900μg/μlf o r3d a y s
then maintained under selection pressure indeﬁnitely at a
concentration of 400μg/μl. KU812 stable lines were treated
with the various drugs at the same concentrations described
above. FK228 and analogues were screened at concentrations
between1–1000nMfor48hrandcelltoxicitywasmonitored
by 2% Trypan blue exclusion. The eﬀect of drug treatments
on γ-globin and β-globin promoter activity was monitored
by luciferase assay.
2.4. Dual Luciferase Assay. Luciferase activity was monitored
under the diﬀerent experimental conditions using the Dual
Luciferase Assay Reporter System (Promega, Madison, WI).
The activity of ﬁreﬂy luciferase represents γ-globin promoter
activity (γF), while the renilla luciferase is the read-out for
β-globin promoter activity (βR). The β-globin promoter was
strategically cloned between the LCR and γ-globin promoter
to increase β expression, while simultaneously increasing the
sensitivity of detection of γ-globin gene inducers [40].
After drug treatments, KU812 stable cells were washed
with 1X phosphate buﬀered saline and lysed in 1X Passive
Lysis Buﬀer for 15min, then protein extracts were added to
the Luciferase Assay Reagent II and ﬁreﬂy luciferase activity
quantiﬁedinaTurnerDesignsTD-20/20luminometer(Sun-
nyvale,CA).TomeasureβRactivity,Stop&GloReagentswas
added to measure the renilla luciferase activity. Total protein
w a sd e t e r m i n e db yB r a d f o r da s s a yo naB e c k m a nD U6 4 0
spectrophotometer (Chaska, MN) and luciferase activity was
corrected for total protein.Anemia 5
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Figure 2:KnownHbFinducersactivateγ-globinexpressioninKU812cells.(a)Inductionofγ-globintranscriptionbyknownHbFinducers.
Cells were treated for 48hr with the diﬀerent drug inducers and γ-globin and β-globin gene transcription were measured by RT-qPCR (see
Section 2). The relative mRNA levels were plotted as fold increase. Untreated cells (UT) were used as a control and normalized to one. Data
werecalculatedasthemeans ±standarderrorofthemean(SEM); ∗P<0.05and ∗∗P<0.01.(b)Shownisaschematicofthedualluciferase
reporter construct μLCRβprRlucγprFluc which contains a 3.1-kb μLCR cassette linked to a 315-bp human β-globin gene promoter driving the
renilla luciferase gene and a 1.4-kb Aγ promoter driving the ﬁreﬂy luciferase gene [33, 39].
2.5. Two-Phase Erythroid Liquid Culture System. The two-
phase liquid culture system was established as previously
published by Fibach et al. [41] using buﬀy coat mononuclear
cells, purchased from Carter Blood Care (Fort Worth, TX)
in accordance with the guidelines of the Institutional Review
Board at the University of Texas at Dallas. During phase 1,
cells were grown in IMDM medium with 30% fetal bovine
serum and 50ng/mL each of the granulocyte-monocyte
colony-stimulatingfactor,Interleukin-3, andstemcellfactor.
Subsequently, phase 2 was initiated on day 7 with the
addition of erythropoietin (2U/mL) and stem cell factor
(50ng/mL). The cells were treated on Day 11 with the
diﬀerent test compounds and harvested on Day 14 (72hr
incubation).
2.6. Reverse Transcription—Quantitative PCR (RT-qPCR)
Analysis. Total RNA was isolated from samples using RNA
Stat-60 (TEL-TEST “B” Inc., Friendswood, TX) and used
for RT-qPCR analysis as previously published [42]. Brieﬂy,
cDNA was prepared using the Improm-II reverse transcrip-
tase system and oligo (dT)15 primers (Promega). qPCR was
performed on an iCycler iQ machine (Bio-Rad) using a
master mix containing Sybergreen iQ Supermix (BioRad)
and 100 pM of each gene-speciﬁc primer pairs for γ-
globin, β-globin and the internal control GAPDH. Standard
curves were generated using serial 10-fold dilutions of
Topo7 base plasmids carrying a γ-globin cDNA sequence
(Topo7-γ-globin), Topo7-β-globin, and Topo7-GAPDH.
TheglobinmRNAlevelswerecalculatedasaratioofGAPDH
(γ/GAPDH, β/GAPDH), and the γ/β-globin mRNA ratio
was calculated by dividing γ/GAPDH by β/GAPDH.
2.7. Immunohistochemistry. Primary erythroid progenitor
cytospin cell preparations were ﬁxed with 4% paraformalde-
hyde in phosphate buﬀered saline for 15min, washed,
and then permeabilized with 0.3% Trition-100 solution for
10min. Cells were then blocked in a 5% bovine serum
albumin solution and immunostaining performed at 4◦C
overnight with anti-HbF ﬂuorescein isothiocyanate (FITC)
conjugated antibody (Bethyl Laboratories Inc., TX). Cell
nuclei were stained with mounting medium containing 4 ,6-
diamidino-2-phenylindole (DAPI; Santa Cruz Biotechnol-
ogy,CA).PrimarycellswerephotographedwithanOlympus
BX 51 phase contrast epiﬂuorescent microscope equipped
with Hoﬀman Modulation optics. Phase-contrast images
were recorded with a CCD camera (1/100sec exposure) and
ﬂuorescenceimageswerephotographedthrough485/520nm
emission ﬁlter. The percent of HbF positive cells was
calculated by dividing the number of FITC positive cells by
total cells (DAPI positive).
2.8. Enzyme-Linked Immunosorbent Assay (ELISA). Total
hemoglobin was quantiﬁed using 20μLo fp r o t e i ne x t r a c t
from one million KU812 cells mixed with 5mL of Drabkin’s
reagent (Sigma); then cyanmethemoglobin was measured at
the 540nm wavelength. HbF levels were quantiﬁed using
the human Hemoglobin F ELISA Quantitation Kit (Bethyl
Laboratory, Montgomery, TX). Brieﬂy, 96-well plates were
coated with sheep anti-human HbF antibody (1mg/mL).
After blocking with 1% bovine serum albumin, horse radish
peroxidase-conjugated secondary antibody (1mg/mL) was
added. Raw data were analyzed using GraphPad PRISM
(GraphPad Software, Inc., La Jolla, CA) and HbF levels were
calculated as a ratio of total hemoglobin corrected for total
protein (HbF/total Hb/total protein).
2.9. HDAC Inhibition Assay. The HDAC Fluorescent Activity
Assay (Enzo Life Science, Farmingdale, NY) was used to
measure HDAC inhibition in HeLa cells in a 96-well format
using Trichostatin A as the positive control per the manu-
facturer’s protocol. This assay is based on the Fluor de Lys
(Fluorogenic Histone Deacetylase Lysyl (FDL)) Substrate/
Developer.Theprocedurewasasfollows:thetestcompounds
FK228, JMA26, and JMA33 were added to HeLa cells along6 Anemia
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Figure 3:JMA33andJMA26induceHbFinprimaryerythroidcells.(a)Day11erythroidprogenitorsweretreatedfor48hrwiththecontrols
agents and the FK228 analogues shown and then analyzed by RT-qPCR. Untreated cells (UT) were used as a control and normalized to one.
Data were calculated as the means ± SEM. (b) Progenitors were stained with anti-γ-globin FITC conjugated antibody overnight and HbF
positivecellsforwerevisualized.DAPIstainingwasperformedtoidentifycellnucleiandtodeterminecellcounts.Imageswerephotographed
at 40X power. The images generated were used to count 500 DAPI positive cells and the %FITC positive cells were calculated accordingly.
with the FDL substrate to allow intracellular drug activation
then ﬂuorescence levels were read on the ﬂuorometer at
440nm (CytoFluor II, PerSeptive Biosystems, Farmingdale,
N Y ) .T h ed r u gc o n c e n t r a t i o n st e s t e dw e r eb a s e do nt h e
amount required for HbF induction in primary cells. Data
was reported as the mean ± standard deviation (SD) for at
least ﬁve replicates.
2.10. Statistical Analysis. The data are reported as the
mean ± standard error of the mean (SEM) from at least ﬁve
data points generated from independent drug treatments.
Data were analyzed by a two-tailed student’s t-test, and
values of P<0.05 were considered statistically signiﬁcant.
Statistical analyses were performed using Microsoft Excel
(Redmond, WA, USA).Anemia 7
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Figure 4:HDACinhibitionassay.TheHDACFluorescentActivityAssaywasusedtomeasureHDACinhibitioninHeLacells(SeeSection2).
Compounds and FDL substrate were added to HeLa cells to allow drug activation in vivo then ﬂuorescence levels were quantiﬁed on the
ﬂuorometer at 440nm. (a) Trichostatin A (TSA) was used as the control. (b) Inhibition studies were conducted for FK228 showing maximal
HDAC inhibition at the 300nM concentration. (c) Similar studies were performed for JMA33 and JMA26. The data are reported as the
means ± SEM.
3. Results
3.1. Isosteric Substitutions Do Not Alter the Global Structure
of FK228. For the facile synthesis of FK228 analogues, the
most synthetically challenging moiety, hydroxy-mercapto-
heptenoic acid was modiﬁed to a structure that can be easily
constructed but has the capability of retaining the structure
required for biological activity. We used in silico structure
analysis and molecular modeling to design structural ana-
logues of FK228 that met these requirements and could
be easily synthesized [37]. The design of a novel FK228
analogue is summarized in Figure 1. These compounds
were synthesized by modifying the most synthetically chal-
lenging unit, (3S,4E)-3-hydroxy-7-mercaptoheptenoic acid,
with two isosteric substitutions without altering its global
conformation compared to native FK228. First, the trans-
double bond in the heptenoic acid was replaced by an
isosteric amide bond. Second, the ester bond required to
form the depsipeptide was replaced by another amide bond
for facile ring closure that provided higher synthetic yield
and increased in vivo stability. As shown in Figure 1(b), the
structure of the FK228 analogue was found to be almost
identical in structure (RMSD = 0.20 ˚ A), indicating that the
two isosteric changes neither disturbed the global structure
nor altered the backbone structure compared to FK228.
However, these changes enabled facile and rapid synthesis
using readily available starting materials and high-yielding
reactions.Whileretainingtheoriginalstereochemicalconﬁg-
urations, the functional groups R1 and R2 (Figure 1(b))w e r e
substituted with a variety of amino acids such as Ala, Leu,
Phe, 2-Nal, Thr, Asp, and Lys (Scheme 1) to examine the side
chain consisting of small, large, aromatic, hydrophilic, and
charged alterations.
Twenty FK228 analogues were prepared with high overall
yield (75–90%) and purity (80–94%) using the solid-phase
synthetic strategy. To further characterize the compounds,
selected FK228 analogues were examined by 2D-NMR spec-
troscopy in (dimethyl sulfoxide) DMSOd6 using Double-
quantum ﬁltered, total correlation, and rotating frame
Overhauser eﬀect spectroscopy to conﬁrm structures and
stereochemistry (data not shown). The FK228 analogues
were shown to have outstanding solubility (10mM) in the8 Anemia
Table 1: γ-globin induction in KU812-γF/βRs t a b l el i n e sb yF K 2 2 8d e r i v a t i v e s 1.
Line 1 Drug
concentration
γ/γ+2β
Mean SEM P value Fold
change
Untreated none 0.0402 0.0091 n/a 1
Cys 10mM 0.0388 0.0092 0.8528 0.950
Hemin 50μM 0.1732 0.0399 0.0050 4.325
SAHA 2000nM 0.2157 0.0142 0.0001 5.400
FK228 1.5nM 0.1197 0.0325 0.0150 2.975
1127Ox 1000nM 0.0363 0.0022 0.8167 0.900
JMA1 1.5nM 0.0473 0.0149 0.6720 1.175
JMA2 1.0nM 0.0157 0.0003 0.1629 0.400
JMA12 1000nM 0.0187 0.0009 0.2156 0.475
JMA26 500nM 0.1460 0.0234 0.0004 3.650
JMA33 1000nM 0.1373 0.0117 0.0002 3.425
JMA112 100nM 0.0187 0.0007 0.2156 2.453
Line 2 Drug
concentration
γ/γ+2β
Mean SEM P value Fold
change
Untreated none 0.1573 0.0150 n/a 1
Cys 10mM 0.1200 0.0056 0.1977 0.764
Hemin 50μM 0.6593 0.0839 0.0001 4.261
SAHA 2000nM 0.6500 0.0208 0.0001 4.140
FK228 1.5nM 0.6167 0.0338 0.0001 3.929
1127Ox 1000nM 0.6133 0.0371 0.0001 3.904
JMA1 1.5nM 0.1260 0.0152 0.2896 0.803
JMA2 1.0nM 0.1183 0.0071 0.1814 0.752
JMA12 1000nM 0.1470 0.0027 0.7093 0.936
JMA26 500nM 0.2487 0.0308 0.0153 1.579
JMA33 1000nM 0.3313 0.0256 0.0002 2.108
JMA112 100nM 0.1070 0.0076 0.0938 0.682
Line 3 Drug
concentration
γ/γ+2β
Mean SEM P value Fold
change
Untreated none 0.0721 0.0052 n/a 1
Cys 10mM 0.0860 0.0050 0.1814 1.194
Hemin 50μM 0.2508 0.0153 0.0001 3.486
SAHA 2000nM 0.2520 0.0066 0.0001 3.500
FK228 1.5nM 0.1583 0.0198 0.0007 2.194
1127Ox 1000nM 0.0370 0.0095 0.0076 0.514
JMA1 1.5nM 0.0770 0.0036 0.6179 1.069
JMA2 1.0nM 0.0740 0.0036 0.8463 1.027
JMA12 1000nM 0.0537 0.0023 0.0779 0.750
JMA26 500nM 0.2560 0.0192 0.0001 3.555
JMA33 1000nM 0.5120 0.1765 0.0007 7.111
JMA112 100nM 0.0467 0.0019 0.0216 0.653
1Using three independent KU812-γF/βR stable cell lines, the FK228 analogues were examined for their ability to induce γ-globin. After 48hr drug treatments,
cells were harvested and dual luciferase assay performed. Untreated cells were used as a control and normalized to one. Data were calculated as the means ±
standard error of the mean (SEM).
organic solvents ethanol and DMSO and were stable for over
one year.
3.2. FK228 Analogues Are Potent Inducers of γ-Globin Expres-
sion. We ﬁrst performed drug induction studies in wild
type KU812 cells to determine the ability of analogues
to induce endogenous γ-globin gene transcription. KU812
cells have been classiﬁed as a multipotential leukemia cell
line with the ability to diﬀerentiate down the basophilic
[43, 44], eosinophilic [45] and erythroid/megakaryocyticAnemia 9
lineages [46]. Previous studies from our laboratory demon-
strated that KU812 cells express γ-globin, β-globin and
the erythroid markers CD36, and erythropoietin receptor
[47]. Therefore, we used these cells to perform initial drug
screens to determine the suitability of KU812 cells for our
dual luciferase reporter stable lines. We observed a 1.5- to-
10-fold increase in the γ/β-globin mRNA levels after Hem
(50μM), NaB (2mM), SAHA (2μM)), and FK228 (1.5nM)
treatment (Figure 2(a)). In the untreated and negative
controls, cysteine-treated cells, γ-globin gene expression was
not induced. These data demonstrated that the intracellular
environment in KU812 is conducive to identifying γ-globin
gene activators in our FK228 analogue drug screen.
Subsequently, three independent dual-luciferase reporter
KU812 stable cell lines were established to analyze the
abilityFK228analoguestoinduceγ-globinpromoteractivity
without an eﬀect on β-globin transcription. The stable cell
lines were created with the μLCRβprRlucγprFluc construct
(Figure 2(b)) containing a 3.1-kb μLCR cassette linked to
a 315-bp human β-globin promoter driving the renilla (R)
and a 1.4-kb Aγ-globin promoter driving the ﬁreﬂy (F)
luciferase genes [33, 39]. Since the ﬁreﬂy luciferase gene
(γF) has approximately 50% greater luminescence than the
renilla gene (βR), the renilla activity was multiplied by two
to adjust for the diﬀerence in luminescence [33] yielding
the γ/γ+2β ﬁnal measurement. The FK228 analogues were
examined at concentrations ranging from 1–1000nM in
the three stable lines. After 48-hour treatments, cells were
harvestedandproteinisolatedforluciferaseactivityusingthe
Dual Luciferase Reporter Assay. Of the twenty compounds
tested, ﬁve induced γ-promoter activity. The remaining
agents were either toxic at the concentrations tested or did
not induce γ-globin (data not shown). Table 1 summarizes
the γ-promoter activity for FK228 analogues that were tested
further in primary erythroid cells. Cell viability by Trypan
blue exclusion remained at 90–95% for the concentrations
shown. Of note are the FK228 analogues, JMA26 and JMA33
(Table 2) containing aromatic side chains in the functional
R1 and R2 groups which produced statistically signiﬁcant
γ-promoter activation comparable to FK228. Additional
analogues can be designed based on these observations to
increase potency, while sparing toxicity.
3.3. FK228 Analogues Activate HbF Synthesis in Primary
Erythroid Progenitors. Next, we examined the ability of
the lead FK228 analogues to induce HbF expression in
primary erythroid progenitors grown from peripheral blood
mononuclear cells in the two-phase liquid culture system.
As shown in Figure 3(a), JMA26 and JMA33 induced γ-
globin transcription at the mRNA level 2.1-fold and 3.9-fold,
respectively, compared to a maximal 3.2-fold, induction by
SAHA and FK228. However, FK228 derivatives induce γ-
promoter activity at signiﬁcantly lower drug concentrations
compared to SAHA and Hem. At the concentrations tested,
greater than 90% cell viability was observed in primary cells
at all concentrations tested for the synthesized compounds.
The similarity of these results to those acquired with the
KU812 dual-luciferase reporter cell lines also validates the
system for drug screening.
Table 2: FK228 structural analogues.
FK228 analogues R1 R2
JMA1 Val Ala
JMA2 Val Phe
JMA12 Phe Ala
JMA26 Phe Phe
JMA33 2Nal 2Nal
JMA112 Phe Lys(FITC)
Val: valine; Phe: phenylalanini; Ala: alanine; 2Nal: 2-naphthylmethyl; Lys:
lysine; FITC: ﬂuorescein isothiocyanate.
The next set of studies was performed to determine the
ability of JMA26 and JMA33 to induce HbF in primary
erythroid progenitors. Using anti-HbF ﬂuorescein isothio-
cyanate (FITC) antibody, we observed 15.5% HbF-positive
progenitors at baseline in untreated cells (Figure 3(b)).
Treatment with JMA26 and JMA33 produced 3.0-fold,
and 2.5-fold increase in HbF-positive cells, respectively. A
similar increase in HbF-positive cells, were produced by
hemin, SAHA and FK228 (3.0-fold, 3.2-fold and 3.5-fold).
Complementary ELISA data (Table 3) showed a 1.9-fold
and 2.5-fold increase in HbF levels produced by JMA26 and
JMA33, respectively, compared to a 2.4-fold HbF induction
by FK228. We concluded that these lead compounds have the
capability to induce HbF in physiologically normal primary
erythroid progenitors.
3.4. JMA26 and JMA33 Exhibit HDAC Inhibition Activity.
To ascertain the mechanism of HbF induction by the lead
compounds, we performed an in vivo assay to investigate
the ability of JMA26 and JMA33 to act as HDAC inhibitors.
The HDAC Fluorescent Activity Assay designed to measure
HDAC activity in HeLa cells was completed in a 96-well
format. The assay is based on the fact that the Fluor de Lys
substrate is deacetylated by HDACs to generate a ﬂuorescent
readout. TSA (0.5 to 1000nM) was used to establish the
assay in HeLa cells, showing about 80% HDAC inhibition
in our system (Figure 4(a)). By contrast, FK228 produced
about 85% inhibition at the 300nM concentration, which
produces marked cell toxicity (Figure 4(b)). Similar studies
performed for JMA26 and JMA33 showed 20% and 37%
HDAC inhibition, respectively (Figure 4(c)), suggesting HbF
induction in erythroid cells occurs by other mechanisms.
4. Discussion
Drug-mediated HbF induction remains the best treatment
approach to ameliorate the symptoms and complications of
SCD due to its ability to inhibit hemoglobin S polymeriza-
tion. In addition, HbF provides an eﬀective treatment for
β-thalassemia by correcting globin chain imbalance [48].
Other therapies aimed at the underlying molecular causes of
the β-hemoglobinopathies include hematopoietic stem cell
transplantation [49] and gene therapy involving the transfer
ofnormalγ-orβ-globingenesintohematopoieticstemcells.
Despite promising results and ongoing research, the option
for stem cell transplantation is limited by the lack of suitable10 Anemia
Table 3: Fetal hemoglobin quantiﬁcation in primary erythroid
cells.
Drug
concentration Mean SEM P value Fold
change
Untreated none 0.683 0.0291 n/a 1
Cys 10mM 0.737 0.1201 0.7773 1.079
Hemin 50μM 1.515 0.0405 0.0001 2.218
SAHA 2000nM 1.094 0.1049 0.0197 1.602
FK228 1.5nM 1.676 0.0506 0.0001 2.454
JMA1 1.5nM 0.7953 0.0849 0.2803 1.164
JMA2 1.0nM 0.8120 0.0165 0.0183 1.188
JMA26 500nM 1.3086 0.0535 0.0005 1.916
JMA33 1000nM 1.7223 0.0725 0.0002 2.521
donors for the majority of SCD patients. On the other hand,
gene therapy oﬀers a universal cure but there are concerns
about mutagenesis of target genes due to random vector
integration and the eﬀects of viral sequences on nearby gene
expression [50]. Therefore, pharmacologic HbF induction
remains a viable choice for the development of additional
therapeutic options for treating SCD.
Hydroxyurea is the only drug approved by the Food
and Drug Administration for the treatment of SCD [7, 51],
however, it is not eﬀective in all patients [7] and of minimal
beneﬁt in β-thalassemia [52]. Moreover, there are concerns
about undesirable side eﬀects including long-term carcino-
genesis [53]. Clinical trials with other compounds, such
as arginine butyrate [54] and decitabine [55] have shown
considerable promise, however, orally active preparations
need to be developed to make these agents viable treatment
alternatives.
Formanyyears,K562cellshavebeenusedtoscreenphar-
macological agents as potential HbF inducers. For example,
NaB, decitabine, and hydroxyurea, among others, stimulate
erythroid diﬀerentiation in K562 cells and induce γ-globin
gene transcription [56]. Many HDAC inhibitors including
FK228 are also known to induce HbF. However, synthetic
diﬃculties associated with FK228 production have severely
deterred structure-activity studies to aid understanding of its
mechanismofactionandtoimproveeﬃcacy.Ourdatashows
thatJMA26andJMA33increasedHbFlevelsbyamechanism
independent of HDAC inhibition.
Many published studies have shown that primary ery-
throid cells remain the best system to conﬁrm HbF-inducing
agents and to serve as a predictor of eﬃcacy in vivo.H u m a n
burst forming units—erythroid cells in clonogenic assays
[57] or erythroid progenitors grown in liquid culture [39,
41]—have been used to evaluate putative HbF inducers.
However, these assays are not easily adaptable to large-
scale drug screening, thus immortalized cell lines have
been investigated for this purpose. Previously, FK228 was
tested in the μLCRβprRluc
AγprFluc GM979 stable line [33]
and was shown to induce γ-promoter activity at the 1nM
concentration. We expanded on these studies to establish a
dual-luciferase reporter system. Thus, we used KU812 cells
derived from an individual with chronic myeloid leukemia
[58] because both γ-globin and β-globin are actively tran-
scribed [47]. Moreover, gene proﬁling data generated by
our laboratory showed that KU812 cells express CD36 and
the erythropoietin receptor at levels comparable to day-14
human erythroid progenitors [47].
In this study, when wild-type KU812 cells were treated
with Hem, NaB, SAHA, and FK228, we observed a 3- to
10-fold increase in the γ/β-globin ratio. We next tested
the FK228 analogues in the KU812 dual-luciferase reporter
system created with the μLCRβprRluc
AγprFluc construct. Two
FK228 analogues identiﬁed in the reporter assay, JMA26 and
JMA33,showedeﬃcacyasHbFinducerinprimaryerythroid
progenitors suggesting these compounds have the potential
f o rf u r t h e rd e v e l o p m e n t .
Our last set of experiments was aimed at understanding
the mechanism by which JMA26 and JMA33 induce γ-
globin. Histone acetylation is a highly dynamic reversible
modiﬁcation that contributes to gene expression through
changes in chromatin conformations. The parent compound
FK228 is a class IV cyclic peptide capable of inhibiting Class
I HDAC enzymes (HDAC1, 2, 3, and 8) after intracellular
reduction of its disulﬁde bond by glutathione to produce
the active reduced form of FK228. The functional sulfhydryl
groupﬁtsinsidethecatalyticpocketproducingzincchelation
and inhibition of enzymatic activity [59].
The role of HDAC inhibition in HbF induction has been
investigated by several laboratories. NaB was the ﬁrst agent
shown to mediate histone H3 and H4 hyperacetylation as
a mechanism of HbF induction [60]. Subsequently, many
other HDAC inhibitors such as TSA [42], scriptaid [28],
SBHA (suberohydroxamic acid), and SAHA (suberoylanilide
hydroxamic acid) [59] were shown to be HbF inducers based
onthecentralroleofhistonehyperacetylation.Subsequently,
Perrineandcolleaguesshowedtheabilityofshort-chainfatty
acids to induce γ-globin by displacement of an HDAC3-
NcoR repressor complex [61]. More recently, there exist
chemical genetic screen-identiﬁed HDAC1 and HDAC2 as
molecular targets facilitating drug-mediated HbF induction
[62]. Therefore, to determine the mechanism of action of
JMA26 and JMA33, we completed the HDAC inhibition
assay.
Using the Fluor de Lys system, FK228 produced strong
HDAC inhibition but at a higher concentration (300nM)
than required for HbF induction. Similar studies performed
for JMA26 and JMA33 showed 20% and 37% maximal
inhibition, respectively. These ﬁndings suggest that the
alterations in FK228 structure may have uncoupled HDAC
inhibition activity as the primary mechanism of HbF
induction since higher test drug concentrations did not
produce more HDAC inhibition. These data suggests JMA26
and JMA33 may induce γ-globin by mechanisms other than
targetingHDACs.SincetheFK228analoguesweredeveloped
from a structural library designed by molecular modeling,
additional compounds can be synthesized with greater
HbF inducing potency and selectivity to Class I HDACs.
Additional studies will also be conducted to determine other
mechanisms by JMA26 and JMA33 that induce HbF such
as activation of the p38 mitogen-activated protein kinase or
other signaling pathways [17, 63, 64].Anemia 11
5. Conclusions
The current drug treatment options for SCD are limited
with hydroxyurea being the only FDA-approved drug. The
key ﬁnding of this study is the high-eﬃciency synthesis of
FK228 analogues with structural modiﬁcations which did
not disturb the global chemical structure of the parent
compound. The analogues exhibited HbF induction at
nanomolar concentrations in primary erythroid progenitors
demonstrating physiological relevance. These data support
the FK228 analogues as potential therapeutic agents and
also validates the KU812 dual-luciferase stable cell lines
as an eﬃcacious screening system to identify γ-globin
a c t i v a t o r s .L o n g - t e r mo u rg o a li st oe s t a b l i s hag r o u po fH b F
inducersthatselectivelyinhibitClassIHDACstoexpandour
understanding of epigenetic mechanisms of γ-globin gene
regulation and to facilitate the development of drug therapy
for SCD.
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